Triple-Drug cocktail targets tough lung cancer mutations
NCT ID NCT03567642
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This early-phase trial tests the safety of combining three drugs—osimertinib, a platinum chemotherapy (cisplatin or carboplatin), and etoposide—in people with metastatic EGFR mutant lung cancer that also has changes in the RB1 and TP53 genes. The goal is to find the highest safe dose and understand side effects. Participants have advanced non-small cell lung cancer and may be new to EGFR-targeted therapy or have started osimertinib within the past 9 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib, platinum (cisplatin or carboplatin), and etoposide
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a specific, hard-to-treat form of lung cancer.
- What could go wrong
- This is an early phase 1 trial with only 11 participants, so safety and dosing are still being determined. The combination may cause significant side effects or may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing tube-free lung surgery tested for patients with fragile lungs
- Can standard cancer treatment wake up the immune system? a study investigates.
- Quitlines may double as lung cancer screening boosters
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Text messages and chatbots may help catch lung cancer earlier in underserved communities
- Shorter radiation course may reduce side effects for lung cancer patients